Cardio Diagnostics Holdings, Inc. (CDIO)
NASDAQ: CDIO · IEX Real-Time Price · USD
0.510
-0.020 (-3.72%)
At close: Jul 19, 2024, 4:00 PM
0.507
-0.003 (-0.53%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Company Description
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Cardio Diagnostics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Meeshanthini V. Dogan Ph.D. |
Contact Details
Address: 311 W. Superior Street, Suite 444 Chicago, Illinois 60645 United States | |
| Phone | 855-226-9991 |
| Website | cardiodiagnosticsinc.com |
Stock Details
| Ticker Symbol | CDIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870144 |
| CUSIP Number | 14159C103 |
| ISIN Number | US14159C1036 |
| Employer ID | 87-0925574 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Meeshanthini V. Dogan Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Elisa Michael Luqman Esq., J.D., M.B.A. | Chief Financial Officer |
| Dr. Robert A. Philibert M.D., Ph.D. | Co-Founder, Chief Medical Officer and Director |
| Timur Dogan Ph.D. | Chief Technology Officer |
| Khullani Abdullahi J.D. | Vice President of Revenue and Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 7, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 424B3 | Prospectus |
| Apr 1, 2024 | 10-K | Annual Report |
| Feb 6, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 2, 2024 | 8-K | Current Report |
| Feb 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |